Acuta Capital Partners, Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$141.8M
Q ending 2026-03-31
Prior quarter
$147.3M
Q ending 2025-12-31
Change
-3.8% QoQ · +64.4% YoY
Positions
27
reported holdings
Largest positions
All 27 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Praxis Precision Medicines I | PRAX | Shares | $27.4M | 85K |
| Terns Pharmaceuticals Inc | 430 | Shares | $26.1M | 496K |
| Whitehawk Therapeutics Inc | WHWK | Shares | $11.8M | 3.4M |
| Tango Therapeutics Inc | TNGX | Shares | $9.2M | 442K |
| Bright Minds Biosciences Inc | DRUG | Shares | $8.2M | 112K |
| Sutro Biopharma Inc | STRO | Shares | $6.7M | 269K |
| Erasca Inc | ERAS | Shares | $5.7M | 355K |
| Surrozen Inc | SRZN | Shares | $5.0M | 173K |
| Ocular Therapeutix Inc | OCUL | Shares | $5.0M | 592K |
| Compass Therapeutics Inc | CMPX | Shares | $4.5M | 849K |
| Minerva Neurosciences | NERV | Shares | $4.3M | 710K |
| Moonlake Immunotherapeutics | MLTX | Shares | $3.6M | 192K |
| Argen Se - Adr | ARGX | Shares | $3.4M | 5K |
| Oculis Holding Ag | Shares | $2.6M | 98K | |
| Revolution Medicines Inc | RVMD | Shares | $2.5M | 26K |
| 4D Molecular Therapeutics Inc | Shares | $2.3M | 242K | |
| Amylyx Pharmaceuticals Inc | AMLX | Shares | $2.1M | 151K |
| Taysha Gene Therapies Inc | TSHA | Shares | $2.0M | 439K |
| Ideaya Biosciences Inc | IDYA | Shares | $1.6M | 48K |
| Design Therapeutics Inc | DSGN | Shares | $1.6M | 146K |
| United Therapeutics Corp | UTHR | Shares | $1.3M | 2K |
| Ideaya Biosciences Inc | IDYA | Call | $1.2M | 350 |
| Entrada Therapeutics Inc | TRDA | Shares | $1.1M | 89K |
| Avalo Therapeutics Inc | AVTX | Shares | $908K | 61K |
| Lb Pharmaceuticals Inc | LBRX | Shares | $713K | 29K |
| Maze Therapeutics Inc | MAZE | Shares | $577K | 19K |
| Unicycive Therapeutics Inc | UNCY | Shares | $381K | 58K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.